Published in Clinical Oncology Week, March 29th, 2004
In a recent study, hematologists in England evaluated the results of "reduced-intensity allogeneic stem-cell transplantation using BEAM-alemtuzumab conditioning (carmustine, etoposide, cytosine arabinoside, melphalan, and alemtuzumab 10 mg/d on days -5 to -1) in six United Kingdom transplant centers."
"Sixty-five patients with lymphoproliferative diseases underwent sibling (n=57) or matched unrelated donor (n=8) transplantation," explained R.D. Faulkner and coauthors at Nottingham City Hospital.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Oncology Week